UnicoCell Biomed Co., Ltd.

6794

TW0006794001

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 04/07/2024 am IST			5-day change	1st Jan Change
81.9 ^TWD	-0.61%		+1.24%	-1.33%

05/06	UnicoCell Biomed Co., Ltd. Collaborates with Chang Gung Memorialhospital (Linkou Branch) to Receive Approval for the Cellpreparation Site from the MOHW	CI
14/05	UnicoCell Biomed Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

UnicoCell Biomed Co., Ltd. has completed an IPO in the amount of TWD 131.834 million.

May 10, 2024 at 09:30 am IST

UnicoCell Biomed Co., Ltd. has completed an IPO in the amount of TWD 131.834 million.

Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,273,000
PriceRange: TWD 58

Latest news about UnicoCell Biomed Co., Ltd.

UnicoCell Biomed Co., Ltd. Collaborates with Chang Gung Memorialhospital (Linkou Branch) to Receive Approval for the Cellpreparation Site from the MOHW	05/06	CI
UnicoCell Biomed Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
UnicoCell Biomed Co., Ltd. has completed an IPO in the amount of TWD 131.834 million.	10/05	CI
UnicoCell Biomed Co., Ltd. has filed an IPO in the amount of TWD 155.034 million.	01/04	CI
UnicoCell Biomed Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI

Chart UnicoCell Biomed Co., Ltd.

Duration

Period

More charts

Unicocell Biomed Co Ltd is mainly engaged in the research and development of new adipose stem cell drugs and the application of stem cell technology. The main products include stem cell secretin and cell testing services. The Company's current development projects are divided into human adipose-derived mesenchymal stem cells, autologous adipose stem cell transplantation and cell preparation application products. The clinical trials of human adipose-derived mesenchymal stem cells include the ELIXCYTE-CT21 clinical trial project and the ELIXCYTE-CT31 clinical trial project. Autologous adipose stem cell transplantation is used for large-area burns and difficult wound healing. The cell preparation application products include stem cell secretin, which is a conditioned medium derived from cultured stem cells, used to improve skin dullness and fine lines.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
UNICOCELL BIOMED CO., LTD.	-1.33%	148M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+17.73%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.35%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-48.32%	14.89B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B